Haemonetics Corp's stock fell 5.00% as it crossed below the 5-day SMA amid a broader market decline, with the Nasdaq-100 down 0.51% and the S&P 500 down 0.54%.
The company has successfully acquired Vivasure Medical for €100 million, aiming to enhance its technological capabilities in the large-bore closure market. This acquisition includes an upfront cash payment of €100 million and up to €85 million in contingent consideration based on sales growth, reflecting confidence in Vivasure's advanced PerQseal® Elite system, which is expected to significantly improve clinical safety and efficiency in procedures.
This strategic acquisition positions Haemonetics to leverage Vivasure's innovative technology and clinical data, potentially increasing its market share in the rapidly growing structural heart and endovascular procedure sectors, thereby enhancing its competitive edge.
Wall Street analysts forecast HAE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 88.86 USD with a low forecast of 74.00 USD and a high forecast of 99.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast HAE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 88.86 USD with a low forecast of 74.00 USD and a high forecast of 99.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
4 Hold
0 Sell
Moderate Buy
Current: 68.370
Low
74.00
Averages
88.86
High
99.00
Current: 68.370
Low
74.00
Averages
88.86
High
99.00
Mizuho
Outperform
maintain
$75 -> $90
2025-12-17
Reason
Mizuho
Price Target
$75 -> $90
AI Analysis
2025-12-17
maintain
Outperform
Reason
Mizuho raised the firm's price target on Haemonetics to $90 from $75 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and diagnostics group as part of its 2026 outlook. Despite stock valuations trending back toward two-year highs post the Q3 reports, there is potential for further multiple expansion "under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector," the analyst tells investors in a research note.
Baird
Outperform
maintain
$87 -> $99
2025-12-15
Reason
Baird
Price Target
$87 -> $99
2025-12-15
maintain
Outperform
Reason
Baird raised the firm's price target on Haemonetics to $99 from $87 and keeps an Outperform rating on the shares. The firm updated its model after its proprietary PDT Tracker showed continued strength in Rx's which lends support for second half 2026 upside.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HAE
Unlock Now
JPMorgan
Rohin Patel
Neutral
maintain
$62 -> $74
2025-12-12
Reason
JPMorgan
Rohin Patel
Price Target
$62 -> $74
2025-12-12
maintain
Neutral
Reason
JPMorgan analyst Rohin Patel raised the firm's price target on Haemonetics to $74 from $62 and keeps a Neutral rating on the shares. The firm updated the company's model.
Citi
Buy
to
Neutral
downgrade
$77 -> $88
2025-12-11
Reason
Citi
Price Target
$77 -> $88
2025-12-11
downgrade
Buy
to
Neutral
Reason
Citi downgraded Haemonetics to Neutral from Buy with a price target of $88, up from $77. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.
About HAE
Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
